abrdn Life Sciences Investors (NYSE:HQL) Reaches New 12-Month High – Here’s What Happened

abrdn Life Sciences Investors (NYSE:HQL)’s stock price reached a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $21.72 and last traded at $21.6590, with a volume of 172085 shares traded. The stock had previously closed at $21.37.

abrdn Life Sciences Investors Stock Down 2.5%

The stock’s 50 day moving average is $19.78 and its 200 day moving average is $18.03.

abrdn Life Sciences Investors Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Shareholders of record on Monday, August 24th will be issued a dividend of $0.62 per share. This represents a $2.48 dividend on an annualized basis and a yield of 11.2%. The ex-dividend date is Monday, August 24th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in HQL. Royal Bank of Canada lifted its stake in shares of abrdn Life Sciences Investors by 53.3% during the first quarter. Royal Bank of Canada now owns 73,475 shares of the company’s stock valued at $934,000 after buying an additional 25,542 shares during the period. NewEdge Advisors LLC raised its position in shares of abrdn Life Sciences Investors by 43.1% in the 1st quarter. NewEdge Advisors LLC now owns 32,500 shares of the company’s stock worth $412,000 after buying an additional 9,785 shares during the period. First Trust Advisors LP grew its position in abrdn Life Sciences Investors by 112.2% during the second quarter. First Trust Advisors LP now owns 35,321 shares of the company’s stock valued at $452,000 after acquiring an additional 18,674 shares during the period. Raymond James Financial Inc. grew its holdings in shares of abrdn Life Sciences Investors by 20.3% during the 2nd quarter. Raymond James Financial Inc. now owns 375,960 shares of the company’s stock worth $4,816,000 after purchasing an additional 63,429 shares during the period. Finally, Clough Capital Partners L P purchased a new stake in abrdn Life Sciences Investors during the second quarter worth approximately $318,000. 32.21% of the stock is currently owned by hedge funds and other institutional investors.

abrdn Life Sciences Investors Company Profile

abrdn Life Sciences Investors (NYSE: HQL) is a closed-end management investment company that seeks capital appreciation through investment in the life sciences sector. Established in 1994, the trust focuses on equity and equity-related securities of companies engaged in biotechnology, pharmaceuticals, medical devices, diagnostics and related fields. Its closed-end structure allows portfolio managers to maintain a stable pool of capital, pursue long-term investment strategies and employ leverage when deemed appropriate.

The fund’s portfolio spans both public and private companies, with an emphasis on businesses driving innovation in drug development, gene therapy, precision medicine and healthcare technology.